Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension | Zendy

Sabrina Schweintzger | Zendy; Martin Köestenberger | Zendy; Axel Schlagenhauf | Zendy; Gernot Grangl | Zendy; Ante Burmas | Zendy; Stefan KurathKoller | Zendy; Mirjam Pocivalnik | Zendy; Hannes Sallmon | Zendy; Daniela Baumgartner | Zendy; Georg Hansmann | Zendy; Andreas Gamillscheg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension

Author(s) -

Sabrina Schweintzger,

Martin Köestenberger,

Axel Schlagenhauf,

Gernot Grangl,

Ante Burmas,

Stefan KurathKoller,

Mirjam Pocivalnik,

Hannes Sallmon,

Daniela Baumgartner,

Georg Hansmann,

Andreas Gamillscheg

Publication year - 2020

Publication title -

cardiovascular diagnosis and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.83

H-Index - 22

eISSN - 2223-3660

pISSN - 2223-3652

DOI - 10.21037/cdt.2020.04.01

Subject(s) - medicine , endothelin receptor antagonist , pulmonary hypertension , endothelin receptor , antagonist , pharmacology , cardiology , receptor

Macitentan, a dual endothelin receptor antagonist (ERA), was approved in 2014 for the treatment of adults with idiopathic pulmonary arterial hypertension (PAH). Once-per-day dosing and low potential hepatic toxicity make macitentan an appealing therapeutic option for children with PAH, but reports on its use in pediatric patients are still lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research